Craniopharyngioma is a rare primary benign tumor of the central nervous system occurring in the saddle area or paradoxical area, with an annual incidence of 1.3 to 1.7 per million, accounting for approximately 2% to 5% of primary intracranial tumors, but is the most common intracranial tumor in children, accounting for 5.6% to 15%. Craniopharyngioma is a World Health Organization pathologic grade I tumor [8], but malignant transformation has been reported. The main histological types are enamel and papillary types. The average size of the tumor at the time of initial surgery is 3.5 cm, and the vast majority are cystic or mixed cystic-solid, accounting for approximately 84% to 99% of cases, with only 1% to 16% of purely solid lesions. Because craniopharyngioma is adjacent to important brain structures such as optic tract, hypothalamus, pituitary gland, cavernous sinus, willis artery ring, ventricular system, etc., it leads to severe, complex and diverse clinical manifestations. The most common are neurological deficits, visual impairment, and hypopituitary hypothalamic hypofunction. There are many treatment options for craniopharyngioma, including surgical resection, surgical resection plus external radiotherapy, intracapsular radiotherapy, intracapsular bleomycin chemotherapy, stereotactic radiosurgery, stereotactic fractionated radiotherapy, systemic chemotherapy, etc. The best treatment method remains controversial. For example, the surgical resection rate can vary from 18% to 84%, depending on the location, size, hydrocephalus, calcification, and experience of the surgeon. The long-term prognosis of craniopharyngioma is reported in the early literature with 5-year survival rates of 67%-69% and 10-year survival rates of 43%-77%. However, with advances in neuroendocrinology, neuroradiology, microsurgery, supportive care, and radiation oncology, the 5-year survival rate for craniopharyngioma has reached 80-91% and the 10-year survival rate has reached 83-92.7% in the last few decades. However, even in patients with long-term survival, serious complications such as hypopituitarism, visual impairment, hypothalamic damage, neuropsychological and cognitive impairment, etc., remain. The largest number of surgeries in China reported 309 cases in this group, with a total surgical resection rate of 89.3%; intraoperative pituitary stalk injury of 39.8% and mortality rate of 3.9% at 1 month after surgery; 13.7% of the 167 patients with total tumor resection at an average follow-up of 1.8 years recurred, while 75% of the 32 patients with partial resection recurred within six months. It can be seen that craniopharyngioma has a very high recurrence rate, and the treatment after tumor recurrence is more difficult, and the rate of total resection by surgery again decreases more than 25% compared with the first surgery, while the mortality and disability rate of surgery increases significantly, so conservative surgery is a more realistic choice after craniopharyngioma recurrence. The Department of Neurosurgery at the Naval General Hospital has been treating craniopharyngioma since 1987, and by the end of 2012 the number of cases treated exceeded 1500. The treatment includes almost all the current treatment options. However, the vast majority of the cases we treat are recurrent cystic or cystic solid craniopharyngioma, and the most common treatment is stereotactic cystic fluid aspiration plus isotopic 32P internal radiotherapy. The effective control rate of the lesion within a certain period of time can reach 80% .